Shares of Intellia Therapeutics (NTLA) were down 22.9% yesterday after it announced an update from the ongoing phase III study, evaluating the investigational in vivo genome-editing candidate, nexiguran ziclumeran (nex-z), for treating ATTR amyloidosis with cardiomyopathy (ATTR-CM).Per the company, one of the patients in the phase III MAGNITUDE study, which evaluated nex-z for treating ATTR-CM, experienced grade 4 liver transaminase elevations, indicating a notable increase in liver enzymes. The patient was ...